1KA.F GH RESEARCH PLC DL-025

Healthcare Biotechnology Frankfurt Exchange
17.20 EUR
Close of Nov 11, 2026
10.20 27.00
Market cap
EUR 1.18B
P/E
-
P/B
3.69x
ROE
-19.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1KA.F undervalued?

Graham number

The Graham number of GH RESEARCH PLC DL-025 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GH RESEARCH PLC DL-025 fundamental analysis

No fundamental analysis for GH RESEARCH PLC DL-025 yet.

GH RESEARCH PLC DL-025 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GH RESEARCH PLC DL-025

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebu…

Full company profile